Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rigel Pharmaceuticals' oral Syk inhibitor, R788, has been evaluated in a Phase 2 clinical trial on patients suffering from multiple cancers. These are the patients who have failed to respond to at least one line of therapy.
Subscribe to our email newsletter
Rigel Pharmaceuticals has announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the US National Institutes of Health.
This clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.
The enrolled patients will receive 200mg of R788 twice a day and will be monitored to measure a variety of clinical responses as well as drug safety. The patients will continue to receive R788 in 28-day treatment cycles until disease progression or patient or physician withdrawal occurs.
Moreover, NCI will conduct the clinical trial, Rigel will supply study drug and will receive clinical data and trial results.
Elliott Grossbard, Executive Vice President and Chief Medical Officer of Rigel, said: We value the NCI’s expertise and support in exploring the potential of R788 in treating these solid tumors.
These results may provide another path for further expanding R788’s therapeutic potential, he added.